Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
BNR
Burning Rock Biotech Limited
Biopharma services segment indicates outsourced R&D, clinical testing, and development support.
|
$220.29M |
$21.48
+10.46%
|
|
FENC
Fennec Pharmaceuticals Inc.
Direct product in oncology/supportive care with FDA-approved PEDMARK therapy for cisplatin-induced ototoxicity.
|
$219.59M |
$7.86
-1.19%
|
|
CABA
Cabaletta Bio, Inc.
Core product category: CAR-T cell therapy platform (CARTA) and rese-cel directly produced by Cabaletta.
|
$216.77M |
$2.37
+7.50%
|
|
EDIT
Editas Medicine, Inc.
Core product category: in vivo gene therapy using Editas's gene-editing platform (AsCas12a) delivered via targeted lipid nanoparticles (tLNP).
|
$215.81M |
$2.40
+0.21%
|
|
BDTX
Black Diamond Therapeutics, Inc.
BDTX operates as a biotechnology company focused on oncology therapeutics, i.e., Biotech - Oncology.
|
$215.22M |
$3.77
-2.45%
|
|
OMI
Owens & Minor, Inc.
OMI sells and distributes medical devices and biometric equipment for home healthcare and clinical use.
|
$212.42M |
$2.77
+0.73%
|
|
GNLX
Genelux Corporation
Genelux focuses on oncology-focused viral immunotherapies, categorized under Biotech - Oncology.
|
$211.15M |
$5.59
+5.77%
|
|
HUMA
Humacyte, Inc.
Humacyte's Symvess is a vascular conduit/endovascular device used for extremity vascular trauma—fits Vascular Intervention Devices.
|
$210.63M |
$1.32
+0.38%
|
|
HBB
Hamilton Beach Brands Holding Company
Medical devices & biometrics appropriate to HealthBeacon’s connected health offering.
|
$209.96M |
$15.72
-0.63%
|
|
AARD
Aardvark Therapeutics, Inc. Common Stock
ARD-101 and ARD-201 are oral small-molecule therapeutics targeting satiety pathways for metabolic and rare-disease indications.
|
$209.81M |
$9.67
+3.20%
|
|
CBIO
Crescent Biopharma, Inc.
Crescent Biopharma focuses on oncology therapeutics, explicitly mentioning next-gen cancer biologics and its lead PD-1 x VEGF bispecific and ADCs.
|
$209.50M |
$15.17
+8.36%
|
|
CRGX
CARGO Therapeutics, Inc. Common Stock
CRGX's core offerings are oncology CAR-T therapies (firi-cel, CRG-23), placing it in Biotech - Oncology.
|
$206.13M |
$4.47
|
|
CYDY
CytoDyn Inc.
Leronlimab is a monoclonal antibody therapeutic, aligning CytoDyn with Monoclonal Antibody Therapeutics.
|
$202.19M |
$0.30
|
|
PEPG
PepGen Inc.
PepGen's PGN-EDODM1 is an oligonucleotide therapeutic targeting DM1, aligning directly with Oligonucleotide Therapeutics.
|
$199.75M |
$6.08
+0.50%
|
|
PRQR
ProQR Therapeutics N.V.
ProQR's Axiomer platform uses oligonucleotide-based RNA editing (EONs) to direct ADAR-mediated editing.
|
$198.82M |
$2.33
+8.60%
|
|
RNAC
Cartesian Therapeutics, Inc.
Lead platform is an autologous cell therapy using mRNA CAR-T, a direct cell-therapy product line.
|
$197.62M |
$7.58
+3.55%
|
|
INGN
Inogen, Inc.
Company manufactures medical devices and respiratory care equipment (POCs, SOCs, Simeox), a core medical devices business.
|
$192.53M |
$7.11
+0.28%
|
|
DERM
Journey Medical Corporation
Emrosi is an oral small molecule therapeutic (minocycline extended-release) and represents Journey Medical's flagship product launched in 2025.
|
$190.88M |
$7.83
-0.32%
|
|
CCCC
C4 Therapeutics, Inc.
Lead assets (e.g., cemsidomide) are orally bioavailable small-molecule degraders, fitting the 'Oral Small Molecule Therapeutics' category.
|
$190.74M |
$2.67
+7.86%
|
|
TMCI
Treace Medical Concepts, Inc.
Treace's core bunion correction systems are surgical instruments/devices used in operative procedures.
|
$190.15M |
$3.02
-2.27%
|
|
MDWD
MediWound Ltd.
MediWound's core products are enzymatic proteins/enzymes (NexoBrid, EscharEx) used for wound debridement, aligning with Recombinant Proteins & Enzymes.
|
$189.10M |
$18.00
-1.13%
|
|
INFU
InfuSystem Holdings, Inc.
InfuSystem directly provides infusion pumps and related medical device equipment, plus lifecycle management services.
|
$188.94M |
$9.28
-3.63%
|
|
MXCT
MaxCyte, Inc.
ExPERT medical device platform for cell engineering and its related consumables constitute MaxCyte's core product offerings in healthcare hardware.
|
$186.56M |
$1.76
+3.53%
|
|
QNCX
Quince Therapeutics, Inc.
Quince's AIDE platform is a drug-delivery platform encapsulating drugs in autologous red blood cells.
|
$185.31M |
$3.46
+29.59%
|
|
SMTI
Sanara MedTech Inc.
bone fusion/orthopedic implants (BiFORM, ALLOCYTE Plus) and associated bone void filler (OsStic) place the company in Orthopedic Devices.
|
$184.81M |
$20.77
+1.96%
|
|
ARCT
Arcturus Therapeutics Holdings Inc.
Direct product: vaccines pipeline and KOSTAIVE vaccine production and commercialization.
|
$184.65M |
$6.79
-0.15%
|
|
TLSA
Tiziana Life Sciences Ltd
TLSA's lead product Foralumab is a fully human monoclonal antibody therapeutic, placing the company in Monoclonal Antibody Therapeutics.
|
$184.53M |
$1.80
-1.10%
|
|
SKIN
The Beauty Health Company
High-margin disposable consumables (tips, solutions, serums) sold for Hydrafacial devices create a recurring revenue stream, matching Medical Device Consumables.
|
$183.90M |
$1.46
+5.43%
|
|
RPID
Rapid Micro Biosystems, Inc.
Growth Direct is a diagnostic equipment platform for automated microbial detection used in pharmaceutical QC.
|
$183.03M |
$4.13
-0.48%
|
|
LFMD
LifeMD, Inc.
LifeMD operates as a healthcare services provider with a multi-state medical group and in-house pharmacy; core service delivery.
|
$182.08M |
$3.83
-2.54%
|
|
UTMD
Utah Medical Products, Inc.
Filshie Clip System is a surgical device used in gynecologic procedures, directly aligning with UTMD's Filshie Clip product line.
|
$178.46M |
$55.73
-0.36%
|
Showing page 22 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
